PTC Therapeutics, Inc. (PTCT) News

PTC Therapeutics, Inc. (PTCT): $30.35

-0.27 (-0.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PTCT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 396

in industry

Filter PTCT News Items

PTCT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PTCT News Highlights

  • For PTCT, its 30 day story count is now at 11.
  • Over the past 15 days, the trend for PTCT's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • PTC, BEAT and ESP are the most mentioned tickers in articles about PTCT.

Latest PTCT News From Around the Web

Below are the latest news stories about Ptc Therapeutics Inc that investors may wish to consider to help them evaluate PTCT as an investment opportunity.

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q4 2021 Results - Earnings Call Transcript

PTC Therapeutics, Inc. (PTCT) Q4 2021 Earnings Conference Call February 22, 2022, 16:30 ET Company Participants Kylie O'Keefe - VP, Head of Global Strategic Marketing & Business Intelligence Stuart Peltz - Co-Founder & CEO Matthew Klein - COO Eric Pauwels - Chief Business Officer Emily Hill - CFO Conference Call...

SA Transcripts on Seeking Alpha | February 23, 2022

PTC Therapeutics to Participate at Upcoming Investor Conferences

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences:

Yahoo | February 23, 2022

PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

SOUTH PLAINFIELD, N.J., Feb. 22, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2021. "It is gratifying to see that after two years of investment in the innovation

PR Newswire | February 22, 2022

PTC Therapeutics GAAP EPS of -$2.03 misses by $0.34, revenue of $165.2M beats by $4.12M

PTC Therapeutics press release (NASDAQ:PTCT): Q4 GAAP EPS of -$2.03 misses by $0.34.Revenue of $165.2M (+39.0% Y/Y) beats by $4.12M.

Seeking Alpha | February 22, 2022

PTC Therapeutics (PTCT) Reports Q4 Loss, Tops Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -13.41% and 1.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 22, 2022

PTC Therapeutics Q4 2021 Earnings Preview (NASDAQ:PTCT)

PTC Therapeutics (NASDAQ:PTCT) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, after market close.The consensus EPS Estimate is -$1.55 (-43.5% Y/Y) and the

Seeking Alpha | February 21, 2022

Is a Surprise Coming for PTC Therapeutics (PTCT) This Earnings Season?

PTC Therapeutics (PTCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 18, 2022

PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Should You Buy?

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 15, 2022

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Financial Results

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and year-end 2021 financial results and provide an update on the company's business and outlook on Tuesday, Feb. 22, at 4:30 p.m. ET.

Yahoo | February 8, 2022

FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for Evrysdi® (risdiplam) to expand the indication to include pre-symptomatic infants under 2 months old with spinal muscular atrophy (SMA). If approved, Evrysdi would be the first medicine administered at-home for pre-symptomatic babies with SMA.

Yahoo | January 25, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6252 seconds.